Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS

Neurobiology of Disease

Volumn 31, Issue 1, 2008, Pages 58-73

  Rodriguez Pallares, J ^a   Rey, P ^a   Parga, J A ^a   Munoz A ^a   Guerra, M J ^a   Labandeira Garcia, J L ^a  

^a UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

Author keywords

Angiotensin; Dopamine; Microglia; NADPH oxidase; Neuroinflammation; Parkinson

Indexed keywords

ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; DIPEPTIDYL CARBOXYPEPTIDASE; MESSENGER RNA; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME ACTIVITY; INFLAMMATION; MALE; MESENCEPHALON; MICROGLIA; NERVE CELL CULTURE; NERVE CELL NECROSIS; NERVE DEGENERATION; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ADRENERGIC AGENTS; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BRAIN; CELLS, CULTURED; DOPAMINE; FLUORESCENT ANTIBODY TECHNIQUE; IMMUNOHISTOCHEMISTRY; MICROGLIA; NADP; NERVE DEGENERATION; NEURONS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; REACTIVE OXYGEN SPECIES; RECEPTOR, ANGIOTENSIN, TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 45249101114     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2008.03.003     Document Type: Article

References (68)

1. Allen A.M., MacGregor D.P., Chai S.Y., Donnan G.A., Kaczymarzyk S., Richardson K., Kalnins R., Ireton J., and Mendelsohn F.A.O. Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia. Ann. Neurol. 32 (1992) 339-344
2. Aloisi F., Penna G., Cerase J., Menéndez Iglesias B., and Adorini L. IL-12 production by central nervous system microglia is inhibited by astrocytes. J. Immunol. 159 (1997) 1604-1612
3. Andersen J.K. Oxidative stress in neurodegeneration: cause or consequence. Nat. Med. 10 (2004) S18-S25
4. Babior B. NADPH oxidase: an update. Blood 93 (1999) 1464-1476
5. Babior B.M. NADPH oxidase. Curr. Opin. Immunol. 16 (2004) 42-47
6. Bell L.J., Iversen L.L., and Uretsky N.J. Time course of the effects of 6-hydroxydopamine on catecholamine-containing neurones in rat hypothalamus and striatum. Br. J. Pharmacol. 40 (1970) 790-799
7. Björklund A., Rosenblad C., Winkler C., and Kirik D. Studies on neuroprotective and regenerative effects of GDNF in a partial lesion model of Parkinson's disease. Neurobiol. Dis. 4 (1997) 186-200
8. Block M.L., and Hong J.S. Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism. Prog. Neurobiol. 76 (2005) 77-98
9. Block M.L., Li G., Qin L., Wu X., Pei Z., Wang T., Wilson B., Yang J., and Hong J.S. Potent regulation of microglia-derived oxidative stress and dopaminergic neuron survival: substance P vs. dynorphin. FASEB J 20 (2006) 251-258
10. Brown D.C., Steward L.J., Ge J., and Barnes N.M. Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo. Br. J. Pharmacol. 18 (1996) 414-420
11. Cai H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 96 (2005) 818-822
12. Chabrashvili T., Kitiyakara C., Blau J., Karber A., Islam S., Welch W.J., and Wilcox C.F. Effect of Ang II type 1 and 2 receptors on oxidative stress, renal NAD(P)H oxidase, and SOD expresión. Am. J. Physiol., Regul. Integr. Comp. Physiol. 285 (2003) R117-R124
13. Färber K., Pannasch U., and Kettenmann H. Dopamine and noradrenaline control distinct functions in rodent microglial cells. Mol. Cell. Neurosci. 29 (2005) 128-138
14. Ferrari R., Guardigli G., Cicchitelli G., Valgimigli M., Merli E., Soukhomovskaia O., and Ceconi C. Angiotensin II overproduction: enemy of the vessel wall. Eur. Heart J. 4 Suppl A (2002) A26-A30
15. Gao H.M., Hong J.S., Zhang W., and Liu B. Synergistic dopaminergic neurotoxicity of the pesticide rotenone and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. J. Neurosci. 23 (2003) 1228-1236
16. Gao H.M., Liu B., Zhang W., and Hong J.S. Critical role of microglial NADPH oxidase-derived free radicals in the in vitro MPTP model of Parkinson's disease. FASEB J 17 (2003) 1954-1956
17. Gao H.M., Liu B., Zhang W., and Hong J.S. Synergistic dopaminergic neurotoxicity of MPTP and inflammogen lipopolysaccharide: relevance to the etiology of Parkinson's disease. FASEB J 17 (2003) 1957-1959
18. Gendron L., Payet M.D., and Gallo-Payet N. The angiotensin type 2 receptor of angiotensin II and neuronal differentiation, from observations to mechanisms. J. Mol. Endocrinol. 31 (2003) 359-372
19. Gohlke P., Von Kugelgen S., Jurgensen T., Kox T., Rascher W., Culman J., and Unger T. Effects of orally applied candesartan cilexetil on central responses to angiotensin II in conscious rats. J. Hypertens. 20 (2002) 909-918
20. Gonzalez-Hernandez T., Barroso-Chinea P., De La Cruz Muros I., Del Mar Perez-Delgado M., and Rodriguez M. Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons. J. Comp. Neurol. 479 (2004) 198-215
21. Griendling K.K., Sorescu D., and Ushio-Fukai M. NADPH oxidase. Role in cardiovascular biology and disease. Circulation Res. 86 (2000) 494-501
22. Gundersen H.J.G., Bendsen T.F., Korbo L., Marcussen N., Moller A., and Nielsen K. Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APIMS 96 (1988) 379-394
23. Hanisch U.K., and Kettenmann H. Microglia: active sensor and versatile effector cells in the normal and pathologic brain. Nat. Neurosci. 10 (2007) 1387-1394
24. Hanrott K., Gudmunsen L., O'Neill M.J., and Wonnacott S. 6-hydroxydopamine-induced apoptosis is mediated via extracellular auto-oxidation and caspase 3-dependent activation of protein kinase Cdelta. J. Biol. Chem. 281 (2006) 5373-5382
25. Intebi A.D., Flaxman M.S., Ganong W.F., and Deschepper C.F. Angiotensinogen production by rat astroglial cells in vitro and in vivo. Neuroscience 34 (1990) 545-554
26. Jenkins T.A., Mendelsohn F.A.O., and Chai S.Y. Angiotensin-converting enzyme modulates dopamine turnover in the striatum. J. Neurochem. 68 (1997) 1304-1311
27. Phox distributions in rat brain. Brain Res. 1040 (2005) 178-186
28. Konings C.H., Kuiper M.A., Bergmans P.L., Grijpma A.M., van Kamp G.J., and Wolters E.C. Increased angiotensin-converting enzyme activity in cerebrospinal fluid of treated patients with Parkinson's disease. Clin. Chim. Acta 23 (1994) 101-106
29. Lenaz G. Role of mitochondria in oxidative stress and ageing. Biochim. Biophys. Acta 1366 (1998) 53-67
30. Li J., Culman J., Hortnagl H., Zhao Y., Gerova N., Timm M., Blume A., Zimmermann M., Seidel K., Dirnagl U., and Unger T. Angiotensin AT2 receptor protects against cerebral ischemia-induced neuronal injury. FASEB J 19 (2005) 617-619
31. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAuliffe W.G., Dawson V.L., Dawson T.M., and Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nat. Med. 5 (1999) 1403-1409
32. Lin J.-J., Yueh K.-C., Chang D.-C., and Lin S.-Z. Association between genetic polymorphism of angiotensin-converting enzyme gene and Parkinson disease. J. Neurol. Sci. 199 (2002) 25-29
33. Lopez-Real A., Rey P., Soto-Otero R., Mendez-Alvarez E., and Labandeira-Garcia J.L. Angiotensin-converting enzyme inhibitors reduce oxidative stress and protect dopaminergic neurons in a 6-hydroxydopamine rat model of parkinsonism. J. Neurosci. Res. 81 (2005) 865-873
34. Lou M., Blume A., Zhao Y., Gohlke P., Deuschl G., Herdegen T., and Culman J. Sustained blockade of brain AT1 receptors before and after focal cerebral ischemia alleviates neurologic deficits and reduces neuronal injury, apoptosis, and inflammatory responses in the rat. J. Cereb. Blood Flow Metab. 24 (2004) 536-547
35. McKinley M.J., Albiston A.L., Allen A.M., Mathai M.L., May C.N., McAllen R.M., Oldfield B.J., Mendelsohn F.A.O., and Chai S. The brain renin-angiotensin system: location and physiological roles. Int. J. Biochem. Cell. Biol. 35 (2003) 901-918
36. Mendelsohn F.A.O., Jenkins T.A., and Berkovic S.F. Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat. Brain Res. 613 (1993) 221-229
37. Min K.J., Yang M.S., Kim S.U., Jou I., and Joe E.H. Astrocytes induce hemeoxygenase-1 expression in microglia: a feasible mechanism for preventing excessive brain inflammation. J. Neurosci. 26 (2006) 1880-1887
38. Muñoz A., Rey P., Guerra M.J., Mendez-Alvarez E., Soto-Otero R., and Labandeira-Garcia J.L. Reduction of dopaminergic degeneration and oxidative stress by inhibition of angiotensin converting enzyme in a MPTP model of parkinsonism. Neuropharmacology 51 (2006) 112-120
39. Münzel T., and Keany J.F. Are ACE inhibitors a "magic bullet" against oxidative stress?. Circulation 104 (2001) 1571-1577
40. Noda M., Kariura Y., Pannasch U., Nishikawa K., Wang L., Seike T., Ifuku M., Kosai Y., Wang B., Nolte C., Aoki S., Kettenmann H., and Wada K. Neuroprotective role of bradykinin because of the attenuation of pro-inflammatory cytokine release from activated microglia. J. Neurochem. 101 (2007) 397-410
41. Noh K.M., and Koh J. Induction and activation by Zinc of NADH oxidase in cultured cortical neurons and astrocytes. J. Neurosci. 20 (2000) RC111 (1-5)
42. Nuyt A.N., Lenkei Z., Corvol P., Palkovits M., and Llorens-Cortés C. Ontogeny of angiotensin II type 1 receptor mRNAs in fetal and neonatal rat brain. J. Comp. Neurol. 440 (2001) 192-203
43. Okamura A., Rakugi H., Ohishi M., Yanagitani Y., Takiuchi S., Moriguchi K., Fennessy P.A., Higaki J., and Ogihara T. Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J. Hypertens. 17 (1999) 537-545
44. Przedborski S., and Jackson-Lewis V. Experimental developments in movement disorders: uptake on proposed free radical mechanisms. Curr. Opin. Neurol. 11 (1998) 335-339
45. Qin L., Liu Y., Wang T., Wei S.J., Block M.L., Wilson B., Liu B., and Hong J.S. NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. J. Biol. Chem. 279 (2004) 1415-1421
46. Reaney S.H., Johnston L.C., Langston W.J., and Di Monte D.A. Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp. Neurol. 202 (2006) 434-440
47. Rey P., Lopez-Real A., Sanchez-Iglesias S., Muñoz A., Soto-Otero R., and Labandeira-Garcia J.L. Angiotensin type-1-receptor antagonists reduce 6-hydroxydopamine toxicity for dopaminergic neurons. Neurobiol. Aging 28 (2007) 555-567
48. Rodriguez M., Barroso-Chinea P., Abdala P., Obeso J., and Gonzalez-Hernandez T. Dopamine cell degeneration induced by intraventricular administration of 6-hydroxydopamine in the rat: similarities with cell loss in Parkinson's disease. Exp. Neurol. 169 (2001) 163-181
49. Rodriguez-Pallares J., Quiroz C.R., Parga J.A., Guerra M.J., and Labandeira-Garcia J.L. Angiotensin II increases differentiation of dopaminergic neurons from mesencephalic precursors via angiotensin type 2 receptors. Eur. J. Neurosci. 20 (2004) 1489-1498
50. Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., Suzuki Y., Mezzano S., Plaza J.J., and Egido J. Role of the renin-angiotensin system in vascular diseases. Expanding the field. Hypertension 38 (2001) 1382-1387
51. Saavedra J.M. Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities. Cell. Mol. Neurobiol. 25 (2005) 485-512
52. Sachs C., and Jonsson G. Mechanisms of action of 6-hydroxydopamine. Biochem. Pharmacol. 24 (1975) 1-8
53. Serrano F., Kolluri N.S., Wientjes F.B., Card J.P., and Klann E. NADPH oxidase immunoreactivity in the mouse brain. Brain Res. 998 (2003) 193-198
54. Sohn H.Y., Raff U., Hoffmann A., Gloe T., Heermeier K., Galle J., and Pohl U. Differential role of angiotensin II receptor subtypes on endothelial superoxide formation. Br. J. Pharmacol. 131 (2000) 667-672
55. Soto-Otero R., Méndez-Álvarez E., Hermida-Ameijeiras A., Muñoz-Patiño A., and Labandeira-García J.L. Autoxidation and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants: potential implication in relation to the pathogenesis of Parkinson's disease. J. Neurochem. 74 (2000) 1605-1612
56. Stornetta R.L., Hawelu-Johnson C.L., Guyenet P.G., and Lynch K.R. Astrocytes synthesize angiotensinogen in brain. Science 242 (1988) 1444-1446
57. Suzuki Y., Ruiz-Ortega M., Lorenzo O., Ruperez M., Esteban V., and Egido J. Inflammation and angiotensin II. Int. J. Biochem. Cell. Biol. 35 (2003) 881-900
58. Torres E.M., Meldrum A., Kirik D., and Dunnett S.B. An investigation of the problem of two-layered immunohistochemical staining in paraformaldehyde fixed sections. J. Neurosci. Methods 158 (2006) 64-74
59. Touyz R.M. Reactive oxygen species and angiotensin II signaling in vascular cells - implications in cardiovascular disease. Braz. J. Med. Biol. Res. 37 (2004) 1263-1273
60. Unger T. Inhibiting angiotensin receptors in the brain: possible therapeutic implications. Curr. Med. Res. Opin. 19 (2003) 449-451
61. Walther T., Olah L., Harms C., Maul B., Bader M., Hortnagl H., Schultheiss H.P., and Mies G. Ischemic injury in experimental stroke depends on angiotensin II. FASEB J 16 (2002) 169-176
62. Wang G., Anrather J., Huang J., Speth R.C., Pickel V., and Iadecola C. NADPH oxidase contributes to angiotensin II signalling in the nucleus tractus solitarius. J. Neurosci. 24 (2004) 5516-5524
63. Wang G., Anrather J., Glass M.J., Tarsitano M.J., Zhou P., Frys K.A., Pickel V.M., and Iadecola C. Nox2, Ca2+, and protein kinase C play a role in angiotensin II-induced free radical production in nucleus tractus solitarius. Hypertension 48 (2006) 482-489
64. Wu D.C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.K., Ischiropoulos H., and Przedborski S. Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. J. Neurosci. 22 (2002) 1763-1771
65. Wu D., Teisman P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., and Przedborski S. NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proc. Natl. Acad. Sci. U. S. A. 100 (2003) 6145-6150
66. Yanagitani Y., Rakugi H., Okamura A., Moriguchi K., Takiuchi S., Ohishi M., Suzuki K., Higaki J., and Ogihara T. Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 33 (1999) 335-339
67. Zalba G., San Jose G., Moreno M.U., Fortuño M.A., Fortuño A., Beaumont F.J., and Diez J. Oxidative stress in arterial hypertension. Role of NADPH oxidase. Hypertension 38 (2001) 1395-1399
68. Zhang W., Qin L., Wang T., Wei S.J., Gao H.M., Liu J., Wilson B., Liu B., Zhang W., Kim H.C., and Hong J.S. 3-hydroxymorphinan is neurotrophic to dopaminergic neurons and is also neuroprotective against LPS-induced neurotoxicity. FASEB J 19 (2005) 395-397